Drug Profile
Research programme: respiratory disorders therapeutics - ActivX Biosciences/Kyorin
Alternative Names: AX-9657Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ActivX Biosciences; Kyorin Pharmaceutical
- Developer Kyorin Pharmaceutical
- Class Small molecules
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lung disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in Japan
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in USA
- 26 Mar 2009 Preclinical trials in Lung disorders in Japan (unspecified route)